PT - JOURNAL ARTICLE AU - Weatherald, Jason AU - Bondeelle, Louise AU - Chaumais, Marie-Camille AU - Guignabert, Christophe AU - Savale, Laurent AU - Jaïs, Xavier AU - Sitbon, Olivier AU - Rousselot, Philippe AU - Humbert,Marc Au -Bergeron，Anne Au -Montani，David Ti- BCR -Abl酪氨酸激酶抑制剂的肺并发症AID -10.1183/13993003.00279-2020 DP -2020 OCT 01 TA-欧洲呼吸道//www.qdcxjkg.com/content/56/4/4/2000279.Short 4100 -http：//www.qdcxjkg.com/content.com/content/56/4/4/2000279.full so -eur Respir so -eur Respir J2020 1010101;56 AB-靶向BCR -ABL癌蛋白的酪氨酸激酶抑制剂（TKI）彻底改变了慢性髓性白血病的治疗。伊马替尼成功，开发了第二代和第三代分子。激酶抑制和脱靶效应的不同特征在TKI之间有所不同，TKI会导致广泛的潜在毒性。肺比并发症最常使用达沙替尼观察到，但所有其他BCR-ABL TKI都涉及。胸腔积液是TKI的最常见的肺并发症，通常与达沙替尼和鲍苏替尼有关。肺动脉高压是达沙替尼的一种罕见但严重的并发症，在中断时通常是可逆的。鲍苏替尼和庞替尼也与肺动脉高压相关，而伊马替尼则没有。很少有间质肺疾病与TKIS有关，主要与伊马替尼有关。从机械上讲，达沙替尼通过产生线粒体氧化应激而影响正常的肺内皮内皮完整性，从而诱导内皮细胞凋亡，并诱导内皮性内皮细胞和损害的血管渗透性。 The mechanisms underlying other TKI-related complications are largely unknown. Awareness and early diagnosis of the pulmonary complications of Bcr-Abl TKIs is essential given their seriousness, potential reversibility, and impact on future treatment options for the underlying chronic myelogenous leukaemia.Bcr-Abl tyrosine kinase inhibitors have been associated with certain pulmonary complications, including exudative pleural effusions, chylothorax, interstitial lung disease and pulmonary arterial hypertension https://bit.ly/3cG6QnG